Other supportive therapies in sepsis: An evidence-based review

Critical Care Medicine

Volumn 32, Issue 11 SUPPL., 2004, Pages

  Trzeciak, Stephen ^a,b   Dellinger, R Phillip ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BEMIPARIN; CIMETIDINE; DALTEPARIN; ENOXAPARIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTON PUMP INHIBITOR; RANITIDINE; REVIPARIN; SUCRALFATE; TINZAPARIN;

ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COMPRESSION THERAPY; CONSENSUS DEVELOPMENT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG PREFERENCE; ENTERIC FEEDING; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INTENSIVE CARE; META ANALYSIS; PEPTIC ULCER BLEEDING; PNEUMATIC TOOL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SEPSIS; STOMACH PH; STRESS ULCER; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSFUSION; TREATMENT OUTCOME;

CONSENSUS DEVELOPMENT CONFERENCES; EVIDENCE-BASED MEDICINE; HUMANS; PEPTIC ULCER; PRACTICE GUIDELINES; SEPSIS; STRESS; VENOUS THROMBOSIS;

EID: 8444233553     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000145915.53268.A8     Document Type: Review

References (87)

1. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis; American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Crit Care Med 1992; 20: 864-874
2. Kakkar VV, Corrigan TP, Fossard DP: Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet 1975; 2:45-51
3. Assessment of short-term anticoagulant administration after cardiac infarction: Medical Research Council. BMJ 1969; 1:335-342
4. Drapkin A, Merskey C: Anticoagulant therapy after acute myocardial infarction. JAMA 1972; 222:541-548
5. Warlow C, Beattie AG, Terry G, et al: A double-blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 1973; 2:934-936
6. Kierkegaard A, Norgren L: Graduated compression stockings in the prevention of deep vein thrombosis in patients with acute myocardial infarction. Eur Heart J 1993; 14: 1365-1368
7. Prins MH, Gelsena R, Sing AK, et al: Deep vein thrombosis prophylaxis with a low molecular weight heparin in stroke patients. Haemostasis 1989; 19:245-250
8. McCarthy ST, Turner JJ, Roberston D, et al: Low dose heparin as prophylaxis against deep vein thrombosis after acute stroke. Lancet 1977; 2:800-801
9. Turpie AG, Levine MN, Hirsh J, et al: A double blind randomized trial of ORG 10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; 1:523-526
10. Pingleton SK, Bone RC, Pingleton WW, et al: Prevention of pulmonary emboli in a respiratory intensive care unit. Chest 1981; 79: 647-650
11. Cade JF: High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10:448-450
12. Halkin H, Goldberg J, Modan M, et al: Reduction in mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96:561-565
13. Belch JJ, Lowe DO, Ward AG, et al: Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26:115-117
14. Gardlund B: Randomized, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases: The Heparin Prophylaxis Study Group. Lancet 1996; 347:1357-1361
15. Samama MM, Cohen AT, Darmon JY, et al: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341:793-800
16. Dahan R, Houlbert D, Caulin C, et al: Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 1986; 16:159-164
17. Hirsch DR, Ingenito EP, Goldhaber SZ: Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274:335-337
18. Gallus AS, Hirsh J, Tuttle RJ, et al: Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288:545-551
19. Fraisse F, Holzapfel L, Couland JM, et al: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD: The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161:1109-1114
20. Kupfer Y, Anwar J, Seneviratne C, et al: Prophylaxis with subcutaneous heparin significantly reduces the incidence of deep venous thrombophlebitis in the critically ill. Abstr. Am J Crit Care Med 1999; 159(Suppl):A519
21. Wood KE: Major pulmonary embolism: Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 12: 877-905
22. Risk of and prophylaxis for venous thromboembolism in hospital patients: Thromboembolic Risk Factors Consensus Group. BMJ 1992; 305:567-574
23. Saint S, Matthay M: Risk reduction in the intensive care unit. Am J Med 1998; 105: 515-523
24. Anderson FA, Wheeler HB: Venous thromboembolism: Risk factors and prophylaxis. Clin Chest Med 1995; 16:235-251
25. Wheeler HB, Anderson FA Jr, Cardullo PA, et al: Suspected deep vein thrombosis: Management by impedance plethysmography. Arch Surg 1982; 117:1206-1209
26. Randolph AG, Cook DJ, Gonzales CA, et al: Benefit of heparin in central venous and pulmonary artery catheters: A meta-analysis of randomized controlled trials. Chest 1998; 113:165-171
27. Borow M, Crowley JG: Evaluation of central venous catheter thrombogenicity. Acta Anaesthesiol Scand 1985; 81(Suppl):59S-64S
28. Durbec O, Viviand X, Potie F: Lower extremity deep vein thrombosis: A prospective, randomized, controlled trial in comatose or sedated patients undergoing femoral vein catheterization. Crit Care Med 1997; 25: 1982-1985
29. Carvalho AC, Freeman NJ: How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoagulant conditions. J Crit Illness 1994; 9:51-75
30. Clagett GP, Reisch JS: Prevention of venous thromboembolism in general surgical patients: Results of meta-analysis. Ann Surg 1988; 208:227-240
31. Levine MN, Raskob G, Landfield S, et al: Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108(Suppl):276S-290S
32. Goldhaber SZ, Dunn K, MacDougall RC: New onset of venous thromboembolism among hospitalized patients at Bringham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000; 118:1680-1684
33. Ibrahim EH, Iregui M, Prentice D, et al: Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002; 30:771-774
34. Green D, Hirsh J, Heit J, et al: Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994; 46:89-121
35. Warkentin TE, Levine MN, Hirsh J: Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
36. Hirsh J, Raschke R, Warkentin, et al: Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108(Suppl):258S-275S
37. Bergman JF, Neuhart E: A multicenter randomized, double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1988; 60:407-410
38. Haremberg J, Kallenbach B, Martin CE, et al: Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990; 59:639-650
39. Lechler E, Schramm W, Flosbach CW: The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/ safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996; 26(Suppl 2):49-56
40. Dolovich LR, Ginsberg JS, Douketis JD, et al: A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000; 160:181-188
41. Kleber FX, Witt C, Vogel G, et al: Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease: THE-PRINCE Study Group. Am Heart J 2003; 145:614-621
42. Simmonneau G, Sors H, Charbonnier B, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337:663-669
43. Kakkar VV, Howes J, Sharma V, et al: A comparative, double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of postoperative venous thromboembolism. Thromb Haemost 2000; 83:523-529
44. Breddin HK: Reviparin sodium: A new low molecular weight heparin. Expert Opin Pharmacother 2002; 3:173-182
45. Neely JL, Carlson SS, Lenhart SE: Tinzaparin sodium: A low-molecular-weight heparin. Am J Health Syst Pharm 2002; 59: 1426-1436
46. Amarigiri SV, Lees TA: Elastic compression stockings for the prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000; 3:CD001484
47. Anglen JO, Goss K, Edwards J: Foot pump prophylaxis for deep vein thrombosis: The rate of effective usage in trauma patients. Am J Orthop 1998; 27:580-582
48. Black PM, Crowell RM, Abbott WM: External pneumatic calf compression reduces deep thrombosis in patients with ruptured intracranial aneurysms. Neurosurgery 1986; 18: 25-28
49. Cook DJ, Fuller HD, Guyatt GH, et al: Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377-381
50. Schuster DP, Rowley H, Feinstein S, et al: Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984; 76:623-629
51. Zandstra DF, Stoutenbeek CP: The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis: A prospective cohort study. Intensive Care Med 1994; 20:335-340
52. Fisher RL, Pipkin GA, Wood JR: Stress-related mucosal disease. Crit Care Clin 1995; 11:323-345
53. Tryba M: Research on stress ulcer prophylaxis: Wrong questions, wrong answers? Crit Care Med 1999; 27:16-17
54. Tryba M: Risk of acute stress bleeding and nosocomial pneumonia in ventilated intensive care unit patients: Sucralfate verus antacids. Am J Med 1987; 83:117-124
55. Garvey BM, McCambley JA, Tuxen DV: Effects of gastric alkalinization on bacterial colonization in critically ill patients. Crit Care Med 1989; 17:211-216
56. Layne EA, Mellow MH, Lipman TO: Insensitivity of guaiac slide test for detection of blood in gastric juice. Ann Intern Med 1981; 94:774-776
57. Schentag JJ: False positive "hemoccult" reaction with cimetidine. N Engl J Med 1980; 303:110
58. Lacroix J, Infante-Rivard C, Jenicek M, et al: Prophylaxis of upper gastrointestinal bleeding in intensive care units: A meta-analysis. Crit Care Med 1989; 17:862-886
59. Cook DJ, Reeve BK, Guyatt GH, et al: Stress ulcer prophylaxis in critically ill patients: Resolving discordant meta-analysis. JAMA 1996; 275:308-314
60. Friedman CJ, Oblinger MJ, Suratt PM, et al: Prophylaxis of upper gastrointestinal hemorrhage in patients requiring mechanical ventilation. Crit Care Med 1982; 10:316-319
61. Peura DA, Johnson LF: Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 1985; 103: 173-177
62. Zinner MJ, Zuidema GD, Smith P, et al: The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet 1981; 153:214-220
63. Basso N, Bagarani M, Materia A, et al: Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Am J Surg 1981; 141:339-342
64. Skillman JJ, Bushnell LS, Goldman H, et al: Respiratory failure, hypotension, sepsis and jaundice: A clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach. Am J Surg 1969; 117: 523-530
65. Cook D, Guyatt G, Marshall J, et al: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998; 338:791-797
66. Hastings PR, Skillman JJ, Bushnell L, et al: Antacid titration in the prevention of acute gastrointestinal bleeding. N Engl J Med 1978; 298:1041-1045
67. Groll A, Simon JB, Wigle RD, et al: Cimetidine prophylaxis for gastrointestinal bleeding in an intensive care unit. Gut 1988; 27: 135-140
68. Ben-Menachem T, Fogel R, Patel RV, et al: Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit: A randomized, controlled, single-blind study. Ann Intern Med 1994; 121:568-575
69. Bresalier RS, Grendell JH, Cello JP, et al: Sucralfate versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients. Am J Med 1987; 83:110-116
70. Tryba M, Zevounou F, Torok M, et al: Prevention of acute stress bleeding with sucralfate, antacids or cimetidine. Am J Med 1985; 79(Suppl 2C):55-60
71. Luk GD, Summer WR, Messersmith JF: Cimetidine and antacid in prophylaxis of acute gastrointestinal bleeding: A randomized, double blind, controlled study. Abstr. Gastroenterology 1982; 82:1121
72. Priebe HJ, Skillman JJ, Bushnell LS, et al: Antacid versus cimetidine in preventing acute gastrointestinal bleeding. N Engl J Med 1980; 302:426-430
73. Cook DJ, Witt LG, Cook RJ, et al: Stress ulcer prophylaxis in the critically ill: A meta-analysis. Am J Med 1991; 91:519-527
74. Bonten MJM, Gaillard CA, Van der Geest S, et al: The role of intragastric acidity and stress ulcus prophylaxis on colonization and infection in mechanically ventilated ICU patients. Am J Respir Crit Care Med 1995; 152: 1825-1834
75. Prod'hom G, Leuenberger P, Koerfer J, et al: Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine or sucralfate for stress ulcer: A randomized controlled trial. Ann Intern Med 1994; 120: 653-662
76. Hanisch EW, Encke A, Naujoks F, et al: A randomized, double-blind trial for stress ulcer prophylaxis shows no evidence of increased pneumonia. Am J Surg 1998; 176: 453-457
77. Borrero E, Bank S, Margolis I, et al: Comparison of antacid and sucralfate in the prevention of gastrointestinal bleeding in patients who are critically ill. Am J Med 1985; 79:62-64
78. Poleski MH, Spanier AH: Cimetidine versus antacids in the prevention of stress erosions in critically ill patients. Am J Gastroenterol 1986; 81:107-111
79. Stothert JC, Simonowitz DA, Dellinger EP, et al: Randomized prospective evaluation of cimetidine and antacid control of gastric pH in the critically ill. Ann Surg 1980; 192: 169-174
80. Netzer P, Gaia C, Sandoz M, et al: Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999; 94:351-357
81. Jung R, MacLaren R: Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002; 36: 1929-1937
82. Noble D: Proton pump inhibitors and stress ulcer prophylaxis: Pause for thought? Crit Care Med 2002; 30:1175-1176
83. Pingleton SK, Hadzima SK: Enteral alimentation and gastrointestinal bleeding in mechanically ventilated patients. Crit Care Med 1983; 11:13-16
84. American Thoracic Society: Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies. Am J Respir Crit Care 1995; 153:1711-1725
85. MacLaren R, Jarvis CL, Fish DN: Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother 2001; 35:1614-1623
86. Ben-Menachem T, McCarthy BD, Fogel R, et al: Prophylaxis for stress-related gastrointestinal hemorrhage: A cost effectiveness analysis. Crit Care Med 1996; 24:338-345
87. Lam NP, Le PDT, Crawford SY: National survey of stress ulcer prophylaxis. Crit Care Med 1999; 27:98-103